Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GPX-150 in Soft Tissue Sarcoma
NCT02267083Phase 2Completed
- Sponsor
- Gem Pharmaceuticals
- Start
- Jan 2015
- Primary completion
- Nov 2015
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camsirubicin in soft tissue sarcoma (STS), sponsored by Gem Pharmaceuticals. Primary endpoint: Progression-Free Survival at 12 Months. Started Jan 2015; status: completed.
02
Drugs
camsirubicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT02267083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02267083.